Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorambucil plus MabThera induction with MabThera maintenance versus observation in older untreated CLL
2008-001612-20Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab and chlorambucil in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Roche. Primary endpoint: Overall tumor response at end of induction. Started Jun 2008; status: completed.
02
Drugs
rituximabchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2008-001612-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001612-20.